Former Vice President, Global Medical Director, Stryker

Life Science Partner recruited Jon Hopper, MBChB, an accomplished physician executive to become Chief Medical Officer for Osiris Therapeutics. Osiris is the leading stem cell company focused on developing products to treat conditions in wound care, orthopedic and sports medicine markets.

Hopper joins Osiris after serving as the Vice President, Global Medical Director at Stryker. In his new role, Hopper will report directly to CEO Lode Debrabandere and oversee medical affairs, clinical development and regulatory affairs globally. He will be responsible for providing high-level market strategy for Osiris’ leadership within regenerative medicine.

“Hopper has a worldview of developing and marketing both orthopedic and wound healing products in the US, Asia and Europe,” notes Tom Callaway, MD, President of Life Science Partner. “He has helped developing clinical and post-marketing plans for complex biologic products including living cells.”

Hopper earned both his Bachelor of Science Degree in Anatomical Studies and his MB ChB from the University of Birmingham, UK.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Former Senior Business Process Analyst, Global Compliance at Boston Scientific

Life Science Partner recruited Jim Schneider, JD to become Manager of Compliance for American Medical Systems, a subsidiary of Endo Health Solutions.

In his new role at AMS, Schneider will have strong business and sales facing responsibilities including training, investigations and the development of new policies across various sales organizations.

Schneider joins AMS after serving as the Senior Business Analyst for the Global Compliance department at Boston Scientific where he was a key member of the team that implemented the first annual CIA Arrangements Audit.

“Smart, engaging, and incredibly resourceful, Schneider has the capability to get the job done under complex circumstances,” states Thomas Callaway, MD, President of Life Science Partner. “He is an excellent communicator and a ‘lead-by-example’ type of manager.”

Schneider earned his Bachelor of Arts in Political Science from Bemidji State University and his Master of Art in Administration and Business Management from Hamline University. He received his Juris Doctor from the William Mitchell College of Law.

Former Chief Financial Officer at INC Research 

Life Science Partner recruited David Gill, MBA to become Chief Financial Officer at EndoChoice. EndoChoice an Atlanta-based company providing physicians with gastrointestinal endoscopy, diagnostics, infection control and imaging products.

David Gill

He was most recently CFO of INC Research, a publicly traded contract research organization. Previously Gill served as the CFO for TransEnterix, leading a $55 M Series B financing, relocating the company headquarters, and leading planning to scale up GMP manufacturing. As CFO for CTI Molecular Imaging, he raised a total of $213 M including an initial public offering to finance the rapid growth. He established a strategic relationship with Siemens that led to the acquisition of the CTI for $1 B.

In his new role at EndoChoice, Gill will work closely with CEO Mark Gilreath to oversee all corporate financial operations. “Gill understands how to use debt, public markets, and private equity to generate significant return for shareholders,” stated Tom Callaway, MD, Founder and President of Life Science Partner. “He has excelled in companies with highly varied technologies and global operations.”

Gill earned his Bachelor Degree in Accounting from Wake Forest University and his MBA from Emory University Goizueta Business School.

Former Senior Vice President, Chief Medical Officer For Given Imaging 

Life Science Partner recruited David Mason, MD to become Vice President, Medical Affairs and Clinical Programs at MiMedx Group, a premier global processor and distributer of human amniotic tissue grafts across multiple therapeutic areas.

Mason joins the MiMedx team from his role at Given Imaging following its acquisition by Covidien earlier this year.

In his new role at MiMedx, Mason will lead the clinical direction and oversight of the company’s product development, research and regulatory compliance. “Mason has the ability and talent to add value to the launch process of small molecules and complex biologics across a range of therapeutic areas,” stated Tom Callaway, MD, Founder and President of Life Science Partner. “In this new role, Mason will oversee Mimedx’ relationship with the FDA and the regulation of these important, tissue-derived products.”

Mason earned his Bachelor of Arts in Chemistry from Williams College in Massachusetts and his MD from Duke University Medical School, North Carolina. Mason is board certified in Internal Medicine and previously specialized in infectious diseases and rheumatology in his private practice.

Former Global Head of Safety Surveillance for Amgen

Life Science Partner recruited Andre Daniels, MBChB, Executive Director, Pharmacovigilance at Amgen to become Vice President, Head of Medical Safety Physicians at Allergan.

In his new role, Daniels will lead a team of physician executives to support the four key commercial franchises and their pipeline of innovative products.

“Daniels has built safety organizations with global portfolios as diverse as oncology, metabolic diseases, and virology,” stated Tom Callaway, MD, MBA, President of Life Science Partner.

During his first eight years at Amgen, Daniels led the Global Head of Safety Surveillance team with accountability for monitoring clinical safety and all post-marketing safety for all Amgen products.

Prior to his roles at Amgen, Daniels was the Director of Medical Review, Global Drug Safety for Gilead Science.  He began his pharmaceutical career at Pfizer and he became the Global Therapeutic Safety Head, supervising a global team for endocrine, metabolic, and cardiovascular product development.

Originally from South Africa, Daniels earned his MBChB from the University of Cape Town. He earned his diploma in Clinical Epidemiology and Biostatistics as well as his Master in Medical Science (Clinical Epidemiology) from the University of Newcastle, Australia.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Former Vice President, Compliance and Integrity Programs for NSF Health Sciences

Life Science Partner recruited Frank Rivas, JD to become Compliance Officer for American Medical Systems, a subsidiary of Endo Health Solutions. 

Rivas was previously the Vice President, Chief Compliance Officer of Spectranetics Corporation, an interventional cardiology medical device company under a Corporate Integrity Agreement with the Office of Inspector General of the Health and Human Services.

Most recently Rivas was the Vice President, Compliance and Integrity Programs for NSF Health Sciences, a consulting firm in the field of compliance and corporate integrity.

“Rivas has the leadership background of building a team under the pressure of a DOJ investigation and a CIA,” states Tom Callaway, MD, President of Life Science Partner.  “Rivas has the concise communication skills and gravitas that can only come with experience.”

Rivas earned his Bachelor of Science degree in Marine Science from the United States Merchant Marine Academy and he received his JD from Washburn University in Topeka.

Former Senior Scientist and Advisor to the Director, Division of Oral Health, Centers for Disease Control and Prevention

Life Science Partner recruited Eugenio Beltran, DMD, MPH, MS, DrPH, Senior Scientist and Advisor to the Director, Division of Oral Health, Centers for Disease Control and Prevention to become Senior Director, Center for Scientific Strategies and Information for the American Dental Association (ADA).

The ADA is the oldest and largest national dental society in the world and is committed to both the public and the dental profession.

In this new role, Beltran will execute the strategies of the Science Institute and Council, as envisioned by the Senior Vice President, Dan Meyer.  “Beltran has an energy that is infectious,” states Tom Callaway, MD, founder and president of Life Science Partner.  “He is a global scientist and who will link the ADA more tightly to its mission to increase the oral health of people worldwide.”

During his tenure at the CDC, Beltran led the evaluation of current recommendations for fluoride in drinking water for the US and he conducted research regarding the epidemiology of dental caries in pre-school children for eight Latin-American countries.

Beltran earned his Bachelor of Science Degree and his Cirujano Dentista (DMD) at the Universidad Peruana Cayetano Heredia in Peru.  After receiving his Master of Public Health and Master of Science from the University of Michigan, he received his Doctor of Public Health from the University of Michigan.

Former Senior Vice President, Quality and Assurance at Smith & Nephew

Life Science Partner recruited Nigel Wilkinson, a seasoned quality assurance executive to become the Vice President, Quality and Regulatory for EndoChoice.

In his new role, Wilkinson will be responsible for managing a global quality and regulatory organization in the United States, Germany, and Israel. Wilkinson will report to the Chief Executive Officer, Mark Gilreath.

“Smart. Polished. Articulate.  I believe that Wilkinson is the prototype of the senior quality and regulatory leader,” states Tom Callaway, MD, President of Life Science Partner.  “He has built and led a global quality affairs organization and has extensive track record of achieving business objectives while successfully balancing regulatory requirements.”

Prior to his new position at EndoChoice, Wilkinson spent much of his career at Smith & Nephew where he played a critical role in merging the new Advanced Surgical Devices Division with the previous Orthopedic and Endoscopy Divisions.

Wilkinson earned his Bachelor of Science Degree in Microbiology and Genetics from the University of London, England.

Former Director, Process Development at Lonza Biologics

Life Science Partner recruited Jesse McCool, an innovative and energetic R&D leader, to become Vice President, Microbial Services for Cytovance Biologics.

Founded in 2003, Cytovance is one of the premier biological contract companies of therapeutic proteins and antibodies from mammalian cell culture to microbial fermentation.

“Jesse brings considerable new microbial cell development savvy and strong leadership skills to help build out this new product line for Cytovance,” said Tom Callaway, MD, President of Life Science Partner.  “His enthusiasm is infectious.”

In his new role at Cytovance, McCool will report to the Chief Scientific Officer and will direct microbial biologics process discovery and development activities.  He will manage partnerships with client organizations to assure strategic and tactical efforts are executed in accordance with global biologics regulatory submissions.

During his tenure at Lonza, McCool was successful in expanding offerings in Microbial Process R&D Services and improving Lonza’s market presence as Director, Microbial Process Development.

McCool earned his Bachelor of Science Degree and PhD in Microbiology from the University of Massachusetts at Amherst.

Former Director, Early Development and Discovery Sciences at Merck

Life Science Partner recruited, Doris Cully, PhD an innovative drug discovery research leader, to become Vice President, Preclinical Development at Cardioxyl Pharmaceuticals.

Developing congestive heart failure therapies, Cardioxyl produces the most advanced technology in the development of proprietary nitroxyl donors for the treatment of acute decompensated heart failure (ADHF).

Doris Cully Pharma

Cully has an extensive background in biochemistry, cell and molecular biology, and translational biomarkers. Prior to accepting the position at Cardioxyl, Cully was the Director, Early Development and Discovery Sciences at Merck where she specialized in Cardiovascular Diseases such as hypertension, acute-decompensated heart failure, and hypertension-associated kidney disease.

In her new role at Cardioxyl, Cully will report to the Chief Scientific Officer and lead a team for the first oral HNO program, including indications for post-acute congestive heart failure and chronic heart failure.

“Cully is a savvy, hands-on scientist who has considerable experience in developing drugs from target to IND,” said Tom Callaway, MD, President of Life Science Partner.  “She can call the tough shots – including doing the critical experiments that results that illuminate critical decision points.”

After being awarded her Bachelor of Science Degree from The State University of New York at Stony Brook, Cully earned her PhD in Biomedical Sciences